Tandemact is a combination of Actos and glimepiride HCl for type 2 diabetes. Takeda believes combining these medications may provide patients with an easier way for diabetes patients to take the two drugs.
Actos is a member of the thiazolidinedione class of “insulin-sensitizing” agents and it directly targets insulin resistance. Glimepiride acts primarily by increasing the amount of insulin produced by the pancreas. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.
“We are very pleased with this approval of Tandemact, which enables us to provide an additional treatment option for the patients with type 2 diabetes,” said Dr Masaomi Miyamoto, general manager of Pharmaceutical Development Division of Takeda.